Abstract: Fluoxetine is the first major drug for treating up the neurological pain associated with depression since the evolution of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) nearly 3 decades earlier. It was the one and only of its kind because of its activity along the selective serotonin reuptake inhibitor (SSRI) which was sanctioned by the United States Food and Drug Administration, offering a good efficacy and a decreased side effects comparatively to TCAs and MAOIs. However, a debate remains active regarding the true mechanism of the drug by which the medical efficacy of fluoxetine is observed, the value of fluoxetine and its related SSRIs to the profession is unquestionable. Prozac has permeated popular culture, helping to raise awareness of depression and to diminish the prevalence of long-standing stigmas associated with this illness. In this Review, we will showcase the history and importance of fluoxetine to neuroscience in general, as well as for the treatment of depression, and review the nature, pharmacology, preclinical reports, and adverse effects of fluoxetine.
Keywords: central nervous system, peripheral nervous system, tricyclic anti-depressants, serotonin-norepinephrine reuptake inhibitors.
Title: A potential impact of Fluoxetine in Neurological Pain: A review
Author: Manish Kumar, Indu Melkani, Bimlesh Kumar, Linu Dash, Anupriya, Varimadugu Bhanukirankumar Reddy, Yousif Al-Daghestani
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
